IL15 and neoplasm: We posit that there are multiple circumstances where IT administration of MS~IL-15 agonists in combination with systemic or local administration of other agents could provide dual benefits of anti-tumor and anti-metastatic effects, without the toxicities associated with systemic IL-15.